Please login to the form below
Namenda
This page shows the latest Namenda news and features for those working in and with pharma, biotech and healthcare.
Forest said to be interested in $3bn Aptalis acquisition
US for former blockbuster antidepressant Lexapro (escitalopram), as well as generic competition from 2015 for Alzheimer's disease therapy Namenda (memantine). ... With Lexapro and Namenda accounting for more than three quarters of company turnover at
Latest news
-
Lundbeck and Otsuka take Alzheimer's drug into phase III
Regardless, it has been 10 years since the last new Alzheimer's treatment reached the market - Lundbeck's glutamate (NMDA) antagonist Ebixa (memantine), which is sold as Namenda by Forest Labs
-
Forest's net income down for Q3
He said: "We have been working diligently for the past seven years to build a solid product development pipeline that will more than replace the loss of Lexapro and Namenda following
-
Forest Laboratories earnings rise
Lexapro (escitalopram) and its Alzheimer's drug Namenda (memantine) lose their patent protection in the coming years. . ... expiration for both Lexapro in 2012 and Namenda in 2015 and provide growth," he said.
-
Lifting the fog
Additionally, a patch formulation of donepezil is in development. Also approved for the treatment of moderate-to-severe AD is memantine (Namenda, Forest Laboratories), which was the first NMDA receptor antagonist
-
Forest Labs earnings fall in Q2
revenues lost due to patent expiration for Lexapro in 2012 and [the Alzheimer's drug] Namenda (memantine) in 2015.".
More from news
Approximately 0 fully matching, plus 13 partially matching documents found.
Latest Intelligence
-
Pharma deals during January 2014
Not disclosed. Adamas. Forest. Completion of studies for the NDA of a fixed dosed combination of Namenda and donepezil, Forest has exclusive US commercialisation rights.
-
Pharma deals during November 2012
Development / commercialisation. Fixed dose combination of Namenda and donepezil for AD.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Featured jobs
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
- Account Director, Healthcare Communications
-
Salary TBC
-
Account Director – UK Office
-
Excellent salary and benefits
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
- FREELANCE Account Director – Healthcare Advertising – London – 3...
-
Competitive Daily Rates
Subscribe to our email news alerts
- Finch Therapeutics bags $53m for microbiome therapies
- MSD taps Austria’s Themis to bolster vaccine pipeline
- Early ‘no’ for GW Pharma’s epilepsy drug, but NICE vows to collaborate
- GSK preps filings for BCMA-targeting multiple myeloma drug
- Behaviour change – is there something missing?
- NICE’s long-serving chief exec Sir Andrew Dillon to step down
PMHub
Fishawack Group of Companies
The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...
Latest intelligence
- Empowered patients: shaking the foundations of healthcare
- Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
- A uniquely English genomic medicine service
- The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
- Blended Intelligence
- Data is the most valued commodity of the modern world. For P&P it's all about the application....
Quick links
Infographics
